# EDGAR Filing Document

**Accession Number:** 0001604950
**File Stem:** 0001193125-25-233469
**Filing Date:** 2025-10
**Character Count:** 11648
**Document Hash:** 462c18911fbedfe80634d0d64989094c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-233469.hdr.sgml**: 20251007

**ACCESSION NUMBER**: 0001193125-25-233469

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251007

**DATE AS OF CHANGE**: 20251007

**EFFECTIVENESS DATE**: 20251007

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** scPharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001604950
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465184075
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-277892
- **FILM NUMBER:** 251379938

**BUSINESS ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-517-0730

**MAIL ADDRESS:**
- **STREET 1:** 25 BURLINGTON MALL ROAD, SUITE 203
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**As filed with the Securities and Exchange Commission on October 7, 2025** 

**Registration No. 333-285933** 

**Registration No. 333-277892** 

**Registration No. 333-270757** 

**Registration No. 333-270758** 

**Registration No. 333-263762** 

**Registration No. 333-254636** 

**Registration No. 333-237361** 

**Registration No. 333-229122** 

**Registration No. 333-227071** 

**Registration No. 333-221677** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1 TO:** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-285933** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-277892** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-270757** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-270758** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-263762** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-254636** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-237361** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-229122** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-227071** 

**FORM S-8 REGISTRATION STATEMENT NO. 333-221677** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## SCPHARMACEUTICALS INC.
**(Exact Name of Registrant As Specified In Its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-5184075** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**25 Mall Road, Suite 203** 

**Burlington, Massachusetts, 01803** 

**(617) 517-0730**

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)** 

**scPharmaceuticals Inc. 2014 Stock** 

**Incentive Plan** 

**scPharmaceuticals Inc. 2017 Stock Option** 

**and Incentive Plan** 

**scPharmaceuticals Inc. 2017 Employee** 

**Stock Purchase Plan** 

**scPharmaceuticals Inc. 2023 Employment** 

**Inducement Award Plan** 

**(Full Title of the Plans)** 

**Michael E. Castagna** 

**Chief Executive Officer** 

**MannKind Corporation** 

**1 Casper Street** 

**Danbury, Connecticut 06810** 

**(818) 661-5000** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **David Thomson, Esq.**<br> **MannKind Corporation**<br> **1 Casper Street**<br> **Danbury, Connecticut 06810**<br> **(818) 661-5000** | **Barbara Borden, Esq.**<br> **Rowook Park, Esq.**<br> **Asa M. Henin, Esq.**<br> **Cooley LLP**<br> **10265 Science Center Drive**<br> **San Diego, California 92121**<br> **(858) 550-6000** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
|  Large accelerated filer | ☐ | Accelerated filer | ☐ |
|  Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging Growth Company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

**DEREGISTRATION OF SECURITIES** 

These post-effective amendments (the "***Post-Effective Amendments***") relate to the following Registration Statements on Form S-8 (each a "***Registration Statement***" and collectively, the "***Registration Statements***"), filed with the Securities and Exchange Commission (the "***SEC***") by scPharmaceuticals Inc., a Delaware corporation (the "***Registrant***") and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereunder under such Registration Statements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-285933)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312525057957/d933070ds8.htm) , registering (i) 205,000 shares of the Registrant's common stock, par value $0.0001 per share ("  ***Common Stock*** "), issuable under the scPharmaceuticals Inc. 2017 Employee Stock Purchase Plan (the "  ***ESPP***") and (ii) 2,003,827 shares of Common Stock issuable under the scPharmaceuticals Inc. 2017 Stock Option and
Incentive Plan (the "  ***2017 Incentive Plan*** "), filed with the SEC on March 19, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-277892)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312524066913/d792184ds8.htm) , registering (i) 205,000 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 1,438,740 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 13, 2024;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-270757)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312523076814/d449713ds8.htm) , registering 205,000 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 1,370,316 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 22, 2023;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-270758)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312523076817/d459189ds8.htm) , registering 500,000 shares of the Registrant's Common Stock, issuable under the scPharmaceuticals Inc. 2023 Employment
Inducement Award Plan, filed with the SEC on March 22, 2023;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-263762)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312522081610/d245452ds8.htm) , registering (i) 205,000 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 1,094,668 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 22, 2022;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-254636)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312521091372/d54058ds8.htm) , registering (i) 205,000 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 1,093,038 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 23, 2021;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-237361)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312520083819/d892943ds8.htm) , registering (i) 194,189 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 776,758 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on March 24, 2020;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-229122)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312519001570/d653147ds8.htm) , registering (i) 185,693 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 742,772 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on January 3, 2019;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-227071)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312518260582/d564209ds8.htm) , registering (i) 205,000 shares of the Registrant's Common Stock, issuable under the ESPP and (ii) 741,389 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on August 28, 2018; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• [<u>Registration Statement on Form S-8 (No. 333-221677)</u>](http://www.sec.gov/Archives/edgar/data/1604950/000119312517348121/d491439ds8.htm) , registering (i) 205,000 shares of the Registrant's Common Stock, issuable under the ESPP, (ii) 1,430,000 shares of Common
Stock issuable under the 2017 Incentive Plan, filed with the SEC on November 20, 2017 and (iii) 1,165,453 shares of Common Stock issuable under the scPharmaceuticals Inc. 2014 Stock Incentive Plan.

------

On August 24, 2025, the Registrant entered into that certain Agreement and Plan of Merger (the "***Merger Agreement***") with MannKind Corporation, a Delaware corporation ("***Parent***"), and Seacoast Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("***Merger Sub***"). Pursuant to the Merger Agreement, on October 7, 2025, Merger Sub merged with and into the Registrant with the Registrant surviving the merger as a wholly-owned subsidiary of Parent (the "***Merger***").

As a result of the Merger, the Registrant has terminated any and all of the offerings and sales of the Registrant's securities pursuant to the Registration Statements. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statements but remain unsold at the termination of the offerings, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statements that remain unsold as of the date hereof, and each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments No. 1 to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Danbury, State of Connecticut, on October 7, 2025.

---

| | |
|:---|:---|
| **scPharmaceuticals Inc.** | **scPharmaceuticals Inc.** |
| By: | /s/ Michael E. Castagna |
| Name: | Michael E. Castagna |
| Title: | President |

---

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.